Major Spanish hospital groups are bringing their diagnostic labs testing in-house, in a trend which stands in direct contrast to what is happening in other countries.
French elderly care giant Orpea continues to hit the headlines for all the wrong reasons. Over the last week, dozens of facilities were raided by the French authorities, talk continues to be rife about restructuring and potential exits, and contrary to previous assertions HBI understands the group now intends to pay back the full €56m owed to the state.
Insurance plan group Simplyhealth have launched a £60m VC fund for early-stage healthcare start-ups in the UK. Its CEO says his firm is well placed to invest sensibly due its contacts, and the current state of the economy.
Amazon has launched its own telehealth platform, Amazon Clinic, on which patients can connect with health care providers in their area and book appointments.
Ali Parsa, the charismatic healthcare entrepreneur who founded digital health company Babylon Health, has branded the company’s stock market performance an “unbelievable, unmitigated disaster” in an interview with the Financial Times.
As the Portuguese NHS continues to flounder, hospital groups such as Luz Saude and CUF are looking to expand their coverage into untouched regions in the country.
The German government has pledged an €8bn support package to help hospitals and care homes tackle inflation and rising energy costs, and promised to end Germany's flat-rate DRG tariff system, but other parts of the the country's under pressure health care sector - particularly smaller lab groups - are struggling to stay afloat.
Having spent the last 10 years of his life building a multi-million revenue company, Dignio founder Lars Dahle has found the last week since he stepped down as CEO rather quiet. HBI catches up with him in reflective mood, as he chats about how he built the business up, and how he really feels about leaving his company's future in others' hands.
Orpea has four months to clean up its finances and reach a new agreement with its creditors on debt restructuring. The conciliation period which it has agreed with the courts has bought it time to consider its options in the face of rising costs and interest rates, and a cooling real estate market. The main proposal under discussion is a debt/equity swap which would result in a drastic dilution of existing shares, but it is hard to see how the numbers could add up. HBI hears from analysts about the tough decisions facing the group.
HBI chats with Paresh Patel, the new CEO of UK-based OCL Vision and former MD of UK, Czechia and Poland-based ophthalmology platform Optegra, about his new role, and the ophthalmology market in general.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
